PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8940498

[Sublingual immunotherapy].

D Nelken
View original source ↗Export metadata ↓

Abstract

We treated 14 patients with severe pollinosis or allergic rhinitis with its specific allergen by the sublingual route. Increasing doses of the allergen were given as drops. There was marked improvement in allergic symptoms in 12. Sneezing, itching of the eyes and rhinitis were practically absent, even in the season and there was substantial reduction in intake of antihistamines as well as in the use of steroid inhalers. Only 1 patient did not improve, while 1 developed severe urticaria to Parietaria judaica vaccine.

Explore related subjects

Administration, SublingualAllergensDesensitization, ImmunologicHumansRhinitisRhinitis, Allergic, SeasonalEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Nelken. 1996. [Sublingual immunotherapy].. https://pubmed.ncbi.nlm.nih.gov/8940498/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Calcium channel antagonists: morbidity and mortality--what's the evidence?

Recent studies have shown an association between the use of calcium channel antagonists for the treatment of hypertension and an increased risk of myocardial infarction, gastrointestinal hemorrhage and cancer. The interpretation of the results of these studies and their application to clinical practice requires an understanding of study design constraints, conflicting results and limitations in extrapolating study findings to other dosage strengths, formulations or agents within the calcium channel antagonist class. A review and critique of these studies provides background information on the controversial subject of using calcium channel antagonists for the treatment of hypertension. Despite the limitations of these studies, clinicians may want to select other classes of agents, including diuretics and beta blockers, as first-line therapy until the morbidity and mortality effects related to the use of calcium channel antagonists are clearly known.

Administration, Sublingual↗
PubMed1998

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis.

BACKGROUND: Non-injective routes of immunotherapy are thought to be valuable therapeutic options for respiratory allergy. We investigated the clinical efficacy and the effects of sublingual/oral immunotherapy on conjunctival allergic inflammation in patients with mite-induced respiratory allergy. METHODS: We used a double-blind placebo-controlled design. 20 patients with mite-induced rhinoconjunctivitis (six of whom also had mild asthma) were randomly assigned sublingual/oral immunotherapy (n=10) or placebo (n=10) for 2 years. We assessed symptom score by diary cards and inflammatory-cell infiltrate, and expression of intercellular adhesion molecule 1 (ICAM-1) in the conjunctiva after specific allergen challenge at enrollment and after 12 and 24 months of treatment. FINDINGS: We found significantly lower symptom scores in the immunotherapy group than in the placebo group in most of the winter months (p=0.05). Compared with the placebo group, inflammatory-cell infiltration after conjunctival challenge, and ICAM-1 expression on conjunctival epithelium decreased significantly in the first year of treatment in the immunotherapy group (p=0.04 and p=0.02, respectively). These effects were also seen for the minimum persistent inflammation, in symptom-free patients exposed constantly to allergens (p=0.02). Serum concentrations of eosinophil cationic protein decreased significantly (p=0.04). Immunotherapy was well tolerated and compliance was good. INTERPRETATION: Our results suggest that this immunotherapy is clinically effective in rhinoconjunctivitis and that it decreases the immune-mediated inflammatory responses to the allergen.

Administration, Sublingual↗